Ramucirumab has shown efficacy in combination with paclitaxel in the second-line treatment of advanced gastric cancer (AGC). The efficacy and safety regarding the combination therapy of ramucirumab and docetaxel have not been reported. This treatment could reduce the incidence of neuropathy and patients’ hospital visits. This was a multicenter, single-arm phase II trial. Patients with AGC who were refractory or intolerant to primary treatment were eligible. Patients received ramucirumab at a dose of 8 mg/kg on day1 and 15, and docetaxel at a dose of 60 mg/m2 on day1 of a 28-day cycle. The primary endpoint was overall response rate (ORR). The secondary endpoints were progression-free survival (PFS), overall survival (OS), relative dose intensity, and safety. A final analysis of efficacy and safety was performed in 35 patients. ORR was 25.7
BACKGROUND:Secondary acute myeloid leukemia (sAML) and AML with myelodysplasia-related changes (AML-MRC) are associated with poor prognosis, but the impact relative to de novo AML remains controversial. We investigated clinical and genetic features in a multicenter Japanese cohort before CPX-351 approval. METHODS:We retrospectively analyzed 294 patients with newly diagnosed AML registered in the Hokkaido Leukemia Net between 2022 and 2023. Propensity score matching was used to adjust baseline variables. Genetic profiles were assessed in 160 matched patients. RESULTS:In the matched cohort, sAML/AML-MRC did not show inferior overall survival compared with non-sAML/non-AML-MRC (P = 0.90). Adverse karyotypes were the predominant determinant among sAML/AML-MRC. Among sAML/AML-MRC patients, adverse karyotypes were associated with poorer survival than those without adverse karyotypes (P = 0.0075). In contrast, non-sAML/non-AML-MRC groups did not affect survival regardless of adverse karyotypes (P = 0.51). Among 65 patients with ELN 2017 adverse-risk, those with TP53 mutations had markedly shorter survival than those with TP53 wild-type (P = 0.018). CONCLUSIONS:sAML/AML-MRC with an adverse karyotype had a dismal outcome. These findings provide a benchmark for risk stratification in the pre- CPX-351 era.
Anamorelin hydrochloride (ANAM), used to treat cancer cachexia, is often discontinued early in clinical practice. Herein, we explored the clinical factors associated with the early discontinuation (Ed) of ANAM and examined its effect on treatment outcomes. Clinical data of patients with gastrointestinal cancers who were administered ANAM between April and November 2021 from 16 institutions were retrospectively collected. Ed was defined as ANAM discontinuation within 4 weeks of initiation. ANAM efficacy was compared between the continuation (Co) and Ed groups. Of the 123 patients, 50 had an Ed of ANAM. The most common reasons were cancer progression (36
Muscle-invasive bladder cancer is molecularly heterogeneous, and the basal/squamous subtype frequently exhibits elevated EGFR expression and TP53 and RB1 alterations. Functional vulnerabilities associated with these alterations remain incompletely defined, while large-scale in vivo screening in mammalian models is experimentally demanding. Therefore, we developed a genotype-defined Drosophila melanogaster model combining Egfr overexpression, mutant p53, and Rbf suppression in Malpighian tubules. The resulting 3-hit model showed increased Malpighian tubule volume and reduced adult eclosion rate. A dominant modifier screen targeting 216 kinase genes identified 72 genes whose perturbation significantly increased the eclosion rate, and a complementary RNA interference screen identified eight kinases whose knockdown increased the eclosion rate. Among these hits, Pka-C3, which is a Drosophila ortholog of human PRKX, emerged as one of the strongest suppressors of the 3-hit phenotype. PRKX was prioritized for further study because public transcriptomic datasets showed higher PRKX expression in bladder tumors than in normal bladder tissue. PRKX knockdown reduced spheroid volume in four human bladder cancer cell lines with distinct EGFR, TP53, and RB1 profiles. Both small interfering RNAs produced significant reductions in two cell lines, whereas only one siRNA reached significance in the other two. These findings nominate PRKX as a candidate vulnerability in bladder cancer and highlight a cross-species approach that combines genotype-informed Drosophila screening with functional testing in human cancer cells to prioritize targets for further investigation. ### Competing Interest Statement Masahiro Sonoshita is a shareholder, co-founder, and Chief Scientific Officer of FlyWorks, K.K. and FlyWorks America Inc. The other authors declare no conflicts of interest. J-PEAKS, PJS00420230001 Japan Science and Technology Agency, https://ror.org/00097mb19, JPMJCR2333 Japan Society for the Promotion of Science Japan Science and Technology Agency, https://ror.org/00097mb19, JPMJSP2119 Nippon Shinyaku Research Grant Program Junior Scientist Promotion Project, Hokkaido University Photo-Excitonix Project, Hokkaido University Joint Research Program of the Institute for Genetic Medicine, Hokkaido University